Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Nephrotic syndrome-associated hyperlipidemia accelerates atherosclerosis and glomerular disease progression.
• HMG-CoA reductase inhibitors reduce cardiovascular events, but their effect on glomerular disease is unclear.
• The Simvastatin in Nephrotic Syndrome Study evaluated simvastatin's impact on kidney function in nephrotic patients.

Purpose of the Study:

• To assess if simvastatin is superior to placebo in slowing GFR decline and reducing proteinuria.
• To determine the efficacy and safety of simvastatin in nephrotic patients.
• To evaluate changes in lipid profiles and renal parameters over two years.

Main Methods:

• A prospective, two-year, double-blind trial involving 56 patients with primary glomerulonephritis and nephrotic syndrome.
• Random assignment to simvastatin or placebo, targeting LDL cholesterol below 120 mg/dl.
• Inulin clearance measured GFR decline; proteinuria changes were also assessed.

Main Results:

• Simvastatin significantly reduced cholesterol (-39%), LDL cholesterol (-47%), and triglycerides (-30%).
• HDL cholesterol showed a minor increase (+1%), and lipoprotein(a) remained unaffected.
• No major adverse events were reported; minor events included asymptomatic creatine kinase elevations.

Conclusions:

• Long-term simvastatin treatment is effective and safe for nephrotic patients with hypercholesterolemia.
• Further evaluation is ongoing for its impact on renal function and proteinuria.